Thursday, February 23rd. 6:30 PM. Beverly Hills, CA
EXCLUSIVE OPPORTUNITY FOR INVESTORS - Groundbreaking Medical Discovery presented by AccenGen Therapeutics, Inc.
AccenGen invites you to participate in a unique opportunity to be an investor in a radical new approach to treating pulmonary fibrosis. AccenGen is a California-based pharmaceutical development company that is racing to bring this vital drug to clinical trials.
Idiopathic pulmonary fibrosis (IPF) is a severe and chronic lung disease of unknown etiology, with a median survival of 2 to 5 years – a prognosis worse than many cancers. IPF is a progressive scarring of the lungs, related to chronic inflammation and other factors, and about 40,000 Americans die from the disease every year. AccenGen’s lead treatment for IPF is a new compound known as an “sEH inhibitor” - a totally new class of anti-inflammatory drugs. AccenGen’s sEH inhibitor compound is backed by research presented in over 800 peer-reviewed studies from top universities including Harvard, Columbia, and the University of California. Click here for bibliography.
Serious investors are invited to attend an invitation-only presentation on AccenGen’s promising drug and to learn about this opportunity that can have a positive impact on millions of patients. Join physicians, scientists, and accredited investors at AccenGen’s upcoming event in Beverly Hills to hear from the company founders and key principals:
· AccenGen’s CEO, Dr. Sassan Rafizadeh, MD, PhD (UC Davis), will present the IPF challenge and treatment with company executives and healthcare leaders.
· Minimum investment is $10,000.
· Dinner will be served.
For further information about the event, please contact Whitney Thompson at Info@AccenGen.com. Event location will be distributed to registered participants only. RSVP below by March 2nd.